医学
切碎
临床试验
内科学
癌症
淋巴瘤
慢性淋巴细胞白血病
肿瘤科
胃肠病学
儿科
白血病
作者
Elizabeth J. Soilleux,Andrew Wotherspoon,Toby A. Eyre,Ruth Clifford,Maité Cabes,Anna Schuh
出处
期刊:Histopathology
[Wiley]
日期:2016-06-27
卷期号:69 (6): 1066-1076
被引量:43
摘要
Aims Richter's syndrome ( RS ) refers to high‐grade transformation of B‐cell chronic lymphocytic leukaemia ( CLL ), usually to diffuse large B‐cell lymphoma, as assessed according to strict World Health Organization ( WHO )‐defined histological criteria. Although this is a relatively evidence‐poor area, the recommended clinical management of high‐grade transformation differs considerably from that of relapsed CLL . The ‘ CHOP ‐ OR ’ trial was a single‐arm, multicentre, non‐randomized phase II National Cancer Research Institute trial in patients with newly diagnosed RS , recruited from across the UK from April 2011 to December 2014. Forty‐three patients were enrolled, of whom 37 were ultimately evaluable for response. The aim was to verify the presence of RS in the trial patients and identify pitfalls in the diagnosis of RS . Methods and results Two independent, specialist haematopathologists reviewed histological material from 40 available cases enrolled in the CHOP ‐ OR trial to determine whether the submitted diagnosis of RS was correct. Three cases were unavailable for central review. This series represents the largest central review of RS within a prospective trial in the literature to date. Thirty‐three of the 40 (82.5%) submitted cases showed features consistent with WHO ‐defined RS . Reasons for diagnostic uncertainty in discrepant cases included large proliferation centres, variably confluent and serpiginous proliferation centres, and an apparently high proliferation index, sometimes attributable to a thick section or associated normal bone marrow proliferation. Conclusions We discuss the importance of high‐quality histological and immunohistochemical sections and strict adherence to WHO criteria in the diagnosis of RS . This study further reinforces the importance of centralized review of cases of haematological malignancy.
科研通智能强力驱动
Strongly Powered by AbleSci AI